Abstract
THE number and diversity of the viruses which infect the upper respiratory tract, and cause the common cold, virtually preclude the control of this disease by conventional vaccines. From this, apart from symptomatic therapy, the only hope for effective treatment of this most prevalent of diseases is in the development of broad spectrum antiviral drugs. We have developed a substituted guanidine, ICI 65,709 (ref. 1) (Fig. 1) which has good activity in vitro against all twenty-five rhinovirus serotypes tested in human embryonic lung cells, and also against certain other picornaviruses.
References
- 1.U.K. Patent No. 1,291,994.
- 2.Bucknall RA. J. gen. Virol. 1967;1:55. doi: 10.1099/0022-1317-1-1-89. [DOI] [PubMed] [Google Scholar]
- 3.Bucknall RA. Advances in Pharmacology and Chemotherapy. 1973. [Google Scholar]
- 4.Rightsel WA, Dice JR, McAlpine JR, Timm EA, McLean IW, Dixon GJ, Schabel FM. Science, N.Y. 1961;134:558. doi: 10.1126/science.134.3478.558. [DOI] [PubMed] [Google Scholar]
- 5.Melnick JL, Crowther D, Barrera-oro J. Science, N.Y. 1961;134:557. doi: 10.1126/science.134.3478.557. [DOI] [PubMed] [Google Scholar]
- 6.Dintner Z, Bengtsson S. Virology. 1964;24:254. doi: 10.1016/0042-6822(64)90164-3. [DOI] [PubMed] [Google Scholar]
- 7.Philipson L, Bengtsson S, Dintner Z. Virology. 1966;29:317. doi: 10.1016/0042-6822(66)90039-0. [DOI] [PubMed] [Google Scholar]
- 8.Loddo B, Gessa GL, Schvo ML, Spanedda A, Brotzu G, Ferrari W. Virology. 1966;28:707. doi: 10.1016/0042-6822(66)90255-8. [DOI] [PubMed] [Google Scholar]